Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin

Biochemistry

Volumn 44, Issue 48, 2005, Pages 15871-15879

  Ravi, Malini ^a   Zask, Arie ^a   Rush III, Thomas S ^b  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CONFORMATIONS; CYTOLOGY; DIMERS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTIMITOTIC AGENTS; BINDING SITES; HEMIASTERLIN; TUBULIN;

PROTEINS;

AMINO ACID; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; HEMIASTERLIN DERIVATIVE; TALTOBULIN; TUBULIN; UNCLASSIFIED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; DRUG BINDING SITE; DRUG CONFORMATION; DRUG MECHANISM; IC 50; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTIMITOTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; ELECTRON SPIN RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

VINCA;

EID: 28544438025     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi051268b     Document Type: Article

References (36)

1. Jordan, M. A. (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin, Curr. Med. Chem.: Anti-Cancer Agents 2, 1-17.
2. Checchi, P. M., et al. (2003) Microtubule-interacting drugs for cancer treatment, Trends Pharmacol. Sci. 24, 361-365
3. Goodin, S., Kane, M. P., and Rubin, E. H. (2004) Epothilones: Mechanism of action and biologic activity, J. Clin. Oncol.: Biology of Neoplasia 22, 2015-2025.
4. Jordan, M. A., and Wilson, L. (2004) Microtubules as a target for anticancer drugs, Nat. Rev. Cancer 4, 253-265.
5. Jordan, A., and Hadfield, J. (1998) Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle, Med. Res. Rev. 18, 259-296.
6. Dumontet, C., and Sikic, B. (1999) Mechanisms of action of and resistance to antitubulin agents: Mictrotubule dynamics, drug transport, and cell death, J. Clin. Oncol. 17, 1061-1070.
7. Altmann, K.-H. (2001) Microtubule stabilizing agents: A growing class of important anticancer drugs, Curr. Opin. Chem. Biol. 5, 424-431.
8. Horwitz, S. B. (1992) Mechanism of action of taxol, Trends Pharmacol. Sci. 13, 134-136.
9. Mathers, C., Shibaya, K., Boschi-Pinto, C., Lopez, A., and Murray, C. (2002) Global and regional estimate of cancer mortality and incidence by site: II. Results for the global burden of disease 2000, BMC Cancer 2, 36-61.
10. Correia, J. J., and Lobert, S. (2001) Physicochemical aspects of tubulin-interacting antimitotic drugs, Curr. Pharm. Des. 7, 1213-1228.
11. Barbier, P., Gregoire, C., Devred, F., Sarrazin, M., and Peyrot, V. (2001) In vitro effect of Cryptophycin-52 on microtubule assembly and tubulin: Molecular modeling of the mechanism of action of a new antimitotic drug, Biochemistry 40, 13510-13519.
12. Nettles, J. H., Li, H., Cornett, B., Krahn, J. M., Snyder, J. P., and Downing, K. H. (2004) The binding mode of epothilone A on I,J-tubulin by electron crystallography, Science 305, 866-869.
13. Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H., and Nogales, E. (2001) The binding conformation of Taxol in J-tubulin: A model based on electron crystallographic density, Proc. Natl. Acad. Sci. U.S.A. 98, 5312-5316.
14. Juménez-Barbero, J., Amat-Guerri, F., and Snyder, J. P. (2002) The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization, Curr. Med. Chem.: AntiCancer Agents 2, 91-122.
15. Rai, S., and Wolff, J. (1996) Localization of the vinblastine-binding site on J-tubulin, J. Biol. Chem. 271, 14707-14711.
16. Mitra, A., and Sept, D. (2004) Localization of the antimitotic peptide and depsipeptide binding site on J-tubulin, Biochemistry 43, 13955-13962.
17. Bai, R. L., Petit, G. R., and Hamel, E. (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites, J. Biol. Chem. 265, 17141-17149.
18. Loganzo, F., Discafani, C., Annable, T., Beyer, C., Musto, S., Hari, M., Tan, X., Hardy, C., Hernandez, R., Baxter, M., Singanallore, T., Khafizova, G., Poruchynsky, M. S., Fojo, T., Nieman, J. A., Ayral-Kaloustian, S., Zask, A., Andersen, R. J., and Greenberger, L. M. (2003) HTI-286, a synthetic analog of the tripeptide hemiasterlin, is a potent anti-microtubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo, Cancer Res. 63, 1838-1845.
19. Krishnamurthy, G., Cheng, W., Lo, M., Aulabaugh, A., Razinkov, V., Ding, W., Loganzo, F., Zask, A., and Ellestad, G. (2003) Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules, Biochemistry 42, 13484-13495.
20. Nunes, M., Kaplan, J., Wooters, J., Hari, M., Minnick, A. A., May, M. K., Shi, C., Musto, S., Beyer, C., Krishnamurthy, G., Qui, Y., Loganzo, F., Ayral-Kaloustian, S., Zask, A., and Greenberger, L. M. (2005) Two photoaffinity analogs of the tripeptide, hemiasterlin, exclusively label I-tubulin, Biochemistry 44, 6844-6857.
21. 1,3-dimethyl-L-valinamide (HTI-286), J. Med. Chem. 47, 4774-4786.
22. Zask, A., Birnberg, G., Cheung, K., Kaplan, J., Niu, C., Norton, E., Yamashita, A., Beyer, C., Krishnamurthy, G., Greenberger, L. M., Loganzo, F., and Ayral-Kaloustian, S. (2004) D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors, Bioorg. Med. Chem. Lett. 14, 4353-4358.
23. Niu, C., Smith, D., Zask, A., Loganzo, F., Discafani, C., Beyer, C., Greenberger, L. M., and Ayral-Kaloustian, S. (2004), Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents, Bioorg. Med. Chem. Lett. 14, 4329-4332.
24. Yamashita, A., Norton, E., Kaplan, J., Niu, C., Loganzo, F., Hernandez, R., Beyer, C., Annable, T., Musto, S., Discafani, C., Zask, A., and Ayral-Kaloustian, S. (2004) Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: Modification of the A segment, Bioorg. Med. Chem. Lett. 14, 5317-5322.
25. Lowe, J., Li, H., Downing, K. H., Nogales, E. (2001) Refined structure of IJ-tubulin at 3.5 Å resolution, J. Mol. Biol. 313, 1045-1057.
26. QUANTA, Accelrys, Inc., San Diego, CA.
27. Nogales, E., Whittaker, M., Milligan, R., and Downing, K. (1999) High-resolution model of the microtubule, Cell 96, 79-88.
28. Sybyl6.9, Tripos, Inc., St. Louis, MO.
29. OMEGA, Open Eye Scientific Software, Santa Fe, NM.
30. FRED, Open Eye Scientific Software, Santa Fe, NM.
31. Verkivker, G. M., Bouzida, D., Gehlaar, D. K., Rejto, P. A., Arthurs, S., Colson, A. B., Freer, S. T., Larson, V., Luty, B. A., Marrone, T., and Rose, P. W. (2000) Deciphering common failures in molecular docking of ligand-protein complexes, J. Comput.-Aided Mol. Des. 14, 731-751.
32. Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., and Mee, R. P. (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes, J. Comput.-Aided Mol. Des. 11, 425-445.
33. Rush, T. S., Manas, E., Tawa, G., and Alvarez, J. (2005) Solvation-based scoring for high throughput docking, in Virtual Screening in Drug Discovery (Alvarez, J., and Shoichet, B., Eds.) pp 241-269, CRC Press, MA.
34. I-substituted analogs, Int. J. Pept. Protein Res. 45, 366-376.
35. Poruchynsky, M. S., Kim, J. H., Nogales, E., Annabel, T., Loganzo, F., Greenberger, L. M., Sackett, D. L., and Fojo, T. (2004) Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analog, HTI-286, have mutations in I- and J-tubulin and increased microtubule stability, Biochemistry 43, 13944-13954.
36. Gigant, B., Curmi, P. A., Martin-Brabey, C., Charbaut, E., Lachkar, S., Lebeau, S., Lebeau, L., Siavoshian, S., Sobel, A., and Knossow, M. (2000) The 4 Å X-ray structure of a tubulin: Stathmin-like domain complex, Cell 102, 809-816.